Indegene Ltd Q2 FY2026 Concall Summary

Key Takeaways

• Revenue up 17% YoY, margin down 2%: Q2 revenue hit ₹804.2 crore with 17.1% YoY growth, but adjusted EBITDA margin compressed to 18.2% as annual wage hikes and deliberate investment spending kicked in.
• Management is investing ahead of the curve: A new ~1.5% near-term margin headwind was announced, funding talent, GenAI infrastructure, and go-to-market build-out, with a stated 6-to-8-quarter timeline to recover to historical ~20%+ margins.
• Two acquisitions closed, integration underway: BioPharm (omnichannel HCP engagement) and WARN & CO (pharma consulting) both completed in October, adding U.S. and U.K. capabilities; support functions integrate in 2 quarters, go-to-market in ~6.
• Large deal ramp is the H2 growth engine: Two deals above ₹0.3 crore ACV start in Q3 and ramp over 3-4 quarters, alongside a biotech commercial deal, a medical device PV deal, and two pharma scope expansions.
• What to watch next quarter: Whether the Brand Activation segment stabilizes after two quarters of degrowth, the pace of Tectonic pipeline conversion, and the actual margin dip from the newly announced investment program.

Revenue & Segment Performance

• Broad-based growth, one drag: Enterprise segment (88.5% of revenue) grew 8.1% QoQ, while Brand Activation degrew 15.8% sequentially, still carrying the full-quarter impact of a project deferral and large project closure that began in Q1.
• Top customer degrowth was expected: The largest customer declined due to a known onsite-to-offshore mix shift negotiated during a past renewal; management flagged this in Q4 FY25 and notes it is margin-positive long-term. Accounts beyond the top 20 grew fastest at 10.3% QoQ.
• Top 5 customers grew 4.5% QoQ despite that largest-customer drag; management is bullish on near-to-midterm growth from this group, citing a strong pipeline.
• Geographic mix steady: North America contributed 69.6% of revenue (vs 70.2% in Q1), Europe 27% (vs 27.1%); over 96% of revenue remains concentrated in the U.S. and Europe.
• Brand Activation pipeline exists but conversion is slow: A win from last quarter has taken off in the current quarter with significant ramp expected in Q3, but new engagement closing has taken more time than anticipated.
• Tectonic hit ~$2M in H1 revenue from 4 paying customers, up from 2 in Q1; multiple conversations initiated and pipeline building fast, with management hopeful to close more in the current quarter given customer planning cycles.

Manish Gupta: "Overall, we see from a demand perspective or quality of engagement perspective, the environment to be much stronger than it was 12 to 18 months back."

Margin Walk & Investment Program

• Q2 margin compression was wage-led: Adjusted EBITDA margin fell 2% QoQ to 18.2%, almost entirely from annual wage increments effective July 1, 2025, a pattern consistent with the historical ~2.1% sequential dilution. Favorable productivity was offset by higher marketing spend (IDS 2025 event) and increased technology costs for cloud, GenAI subscriptions, and infrastructure.
• New investment program adds ~1.5% headwind: Management announced ahead-of-the-curve investments in talent, GenAI capabilities, and go-to-market strengthening that will compress margins by about 1.5% in the near term, starting next quarter. The stated path back is 6 to 8 quarters to return to historical operating levels around 20%+.
• Productivity offsets will be gradual: Management acknowledged opportunities to offset the margin impact through efficiency levers, but expects this to happen progressively through quarters, not within 1-2 quarters.
• Other expenses broke down into three buckets: ~$0.05 crore in M&A diligence and legal fees for the two October acquisitions, ~$0.6M for the IDS 2025 in-person event in Philadelphia, and ~$0.25M in higher technology costs for GenAI subscriptions and cloud infrastructure.
• Interest income declined ~22.5% due to decreasing yields on investments in both the U.S. and India as the Fed and RBI progressively cut rates.
• Revenue per employee is a stated focus: Management believes its revenue per employee is already the highest in the industry and will inch higher; employee growth rate will be kept below revenue growth rate.

Manish Gupta: "The reason we are making these investments is that we see a market opportunity right now. We believe that while there are -- these investments are being made a bit of ahead of the curve, by growth itself, most of the margins will come back on track."

Acquisitions: BioPharm & WARN & CO

• BioPharm (closed October 1, 2025): A U.S.-based omnichannel marketing company focused on targeted HCP engagement. Integration is underway: support functions transition in 2 quarters, business operations and go-to-market integration over ~6 quarters. Gross revenues will be reported per accounting standards, with net revenue also disclosed.
• WARN & CO (closed October 16, 2025): A U.K.-based boutique consulting firm with experience in change management, transformation consulting, and digital and technology for pharma. Upfront consideration was GBP 0.2 crore plus a future performance-linked payout.
• BioPharm growth plan: Management intends to invest to increase business development activity in the U.S. and scale the integrated omnichannel campaign offering globally across brands, leveraging the Enterprise Commercial Solutions segment.

Demand Environment & Industry Context

• Regulatory overhang lifted: The September 30 MFN pricing deal between the Trump administration and Pfizer was characterized as a "big relief" that removes regulatory uncertainty and provides a template for moving forward without significant industry disruption.
• Tariffs and DTC rules have limited direct impact: 100% tariffs on branded and patented drug imports began October 1, with exemptions for manufacturers building U.S. facilities. Tightened DTC marketing regulations on traditional channels drive more engagement through digital and social media, which does not affect Indegene given its lack of significant traditional media DTC engagements.
• H1B visa fee changes are immaterial: Management stated Indegene has low H1B dependency because it is not a staffing business and labor cost arbitrage is not core to its model.
• Pricing pressure plays to Indegene's positioning: Management argued that if drug prices are secularly under pressure, pharma companies must become more efficient and effective, which aligns squarely with Indegene's value proposition.
• No material seasonality in revenue: Management pushed back on the idea of H2 being seasonally stronger, stating the business is not impacted by furloughs or fewer working days. The observed invoicing seasonality (slower July-August) is a cash-flow timing issue from summer vacation delays in customer consent for invoices, not a revenue pattern.

Manish Gupta: "If drug prices are going to be secularly under pressure, companies will have to continue to become more efficient and effective. That plays squarely into our positioning, right? That's where we step in..."

GenAI & Platform Strategy

• Domain contextualization is the core hypothesis: Management sees increasing evidence that real value from GenAI comes from contextualizing the technology for the pharma domain, not from generic models.
• Cortex platform is being built as an agentic layer: Business applications are under development across digital content, agency business, Tectonic, commercial content creation and adaptation, medical legal review, regulatory writing, and submissions, all on a knowledge engineering-led agentic architecture.
• Content Super App in development: A single platform for brand managers and global commercial operations, embedding multiple agents for ideation, concepting, localization, personalization, and regulatory approval.
• Medical writing platform automates end-to-end regulatory authoring: From protocol authoring to clinical study reports to ongoing post-approval filings, with regional use cases still being added.
• Tectonic is small but accelerating: ~$2M in H1 revenue from 4 customers; pipeline is building fast and management is hopeful to close more in the current quarter.

Manish Gupta: "We are increasingly seeing evidence that supports our hypothesis that real value addition from GenAI will come from contextualizing the technology for the domain."

Cash Flow & Balance Sheet

• H1 operating cash flow improved to ₹200 crore from ₹135 crore in the prior year.
• AR has been on a declining trend over 2-3 years, though December typically sees peak invoicing that lifts DSO and AR before converting to cash in March, consistent with a 60-90 day credit period.
• Invoicing slowness in July-August is a timing issue: summer vacations in Europe and the U.S. delay customer consent for invoices, impacting cash flow timing but not revenue recognition.
• Rupee depreciation created a favorable exchange gain, offset by a mark-to-market charge on forwards outstanding at quarter end.

Guidance & Commitments

Key Metrics